Q4 2025 Management View CEO Mitchell Steiner highlighted Veru's transition to a pure-play late clinical stage ...

The stock price of Veru Inc. (NASDAQ: VERU), a biopharmaceuticals company focused on oncology medicines, has seen a monstrous 112% rise over the last ten trading days, while it’s up 47% over the last ...

MIAMI, FL, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for preserving muscle for high quality ...

Veru Inc. (NASDAQ: VERU) will release earnings results for its fourth quarter before the opening bell on Wednesday, Dec. 17.

Q4 2025 Earnings Call Transcript December 17, 2025 Veru Inc. beats earnings expectations. Reported EPS is $0.05, expectations ...

Following positive efficacy and safety results from Phase 2b QUALITY study, company received FDA regulatory clarity for ...

Veru (NASDAQ: VERU) will release its quarterly earnings report on Wednesday, 2025-12-17. Here's a brief overview for ...

MIAMI, Feb. 23, 2021 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), an oncology biopharmaceutical company with a focus on developing novel medicines for the management of prostate cancer and breast ...

To join the conference call via telephone, please dial 1-800-341-1602 (domestic) or 1-412-902-6706 (international) and ask to join the Veru Inc. call. An archived version of the audio webcast will be ...

Veru's valuation has both soared and crashed in 2022 due to its COVID-19 drug. The company recently reported underwhelming earnings numbers, which only gave investors more of a reason to be bearish on ...

Veru's candidate, sabizabulin, appears to be both safe and effective at treating severe COVID-19. The company could get the medicine to the market very quickly if regulators give the green light. The ...